Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis

NCT06857240 Phase 2 RECRUITING

This study will assess the safety and efficacy of topical ruxolitinib for treating the refractory cutaneous manifestations in patients with dermatomyositis. The investigators' hypothesis is that topical ruxolitinib will be both safe and effective for such patients.

Details

Lead sponsor	The Cleveland Clinic
Phase	Phase 2
Status	RECRUITING
Enrolment	15
Start date	2025-06-01
Completion	2027-12

Conditions

• Dermatomyositis

Interventions

• Ruxolitinib Topical Cream

Primary outcomes

• CDASI — 8 weeks
  Change in Cutaneous Dermatomyositis Activity and Severity Index (CDASI) activity score (range 0 - 100; higher scores indicate greater disease activity) at 8 weeks

Countries

United States